- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- Monthly Spotlight
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Virtual Event – Antipsychotic Treatment Options in Schizophrenia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Antipsychotic Treatment Options in Schizophrenia
The treatment of schizophrenia has evolved over the past half-century primarily in the context of antipsychotic drug development. In addition to reviewing the evolution of antipsychotic treatments for schizophrenia, in this virtual live event the speakers will discuss definitions of adherence and review possible reasons for nonadherence, as well as compare evidence supporting oral and long-acting injectable antipsychotics. Lastly, the speakers will explore potential communication strategies for clinicians to assess patient adherence and discuss alternative interventions.
Featuring
-
Martin Guerrero, MD, JD
Forensic and Geriatric Psychiatrist, El Paso, Texas
-
Jessie Chambers, PhD (OPDC)
Medical Science Liaison
Speaker Martin Guerrero, MD, JD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. Speaker Jessie Chambers, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
-
Virtual Event – Plasma Concentrations, Pharmacokinetics & Their Clinical Relevance
October 6 12:00 pm to 1:00 pm -
Virtual Event – Agitation Associated With Alzheimer’s Dementia Disease State Education
October 16 12:00 pm to 1:00 pm
Registration
Related Resources
-
Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
Infographic August 31, 2023 -
1.8% Of U.S. Adults Have Schizophrenia Spectrum Disorders
Article July 17, 2023About 1.8% of adults (ages 18 to 65 years) in the United States have a lifetime history of schizophrenia spectrum disorders, representing 3.7 million people. Schizophrenia spectrum disorders include schizophrenia,…
-
Obesity Increases Risk Of Mental Disorders Throughout Life
Article July 10, 2023Being obese significantly increases the chances of also developing mental disorders. This applies to all age groups, with women at higher risk than men for most diseases. In the case…
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: